Right-sized engagements—from targeted advisories to full program ownership.
Faster approvals, inspection-ready documentation, predictable timelines and spend, and partners who are accountable for delivery.
Oak LS delivers end-to-end clinical and regulatory support tailored to Health Canada and global expectations—lean, accountable, inspection-ready.
Drug (DIN/NDS/SNDS), biologic, device, combination, NHP, or RWE/post-market route; global alignment (FDA/EMA/UK).
Endpoints, populations, comparators, and risk controls engineered to support target labels and access claims.
Health Canada pre-CTA meetings (and FDA pre-IND/EMA Scientific Advice); question packages, briefing books, and rehearsals.
Strategy memos, meeting management, minutes, follow-ups, and regulator correspondence throughout review.
Centralized vs. local REB path, multisite coordination, consent architecture, advertising approvals, and continuing review plans.
CTA → NOL & amendments → pivotal/confirmatory strategy → NDS/SNDS or DIN/NHP filings; global sequencing and reliance options.
Inspection readiness, PV/DSUR/ASR strategy, HEOR/PRO/real-world data linkages, and publication/registry commitments.
Regulatory strategy brief, decision tree, evidence matrix, submission timeline & RACIQ (risks/assumptions/constraints/issues/ queries) log.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.